Search

Flavie Perrier,1 Reza Ghiasvand,2,3 Simon Lergenmuller,1 Trude E Robsahm,3 Adele C Green,4,5 Kristin B Borch,6 Torkjel M Sandanger,6 Elisabete Weiderpass,7 Corina S Rueegg,2 Marit B Veierød1 1Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; 2Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway; 3Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway; 4QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; 5Cancer Research UK Manchester and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; 6Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; 7International Agency for Research on Cancer, Lyon, FranceCorrespondence: Flavie Perrier, Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, PO Box 1122, Blindern, Oslo, N-0317, Norway, Email flavie.perrier@medisin.uio.noPurpose: Physical activity (PA) is a cornerstone in disease prevention and varies throughout life. A pooled analysis of cohort studies and a meta-analysis of cohort studies found positive associations between PA and melanoma risk. However, previous studies focused on PA at specific ages and often lacked information on ultraviolet radiation (UVR) exposure. Using the population-based Norwegian Women and Cancer (NOWAC) cohort, including information on PA and UVR exposure, we estimated life-course PA trajectories from adolescence to adulthood and their associations with melanoma.Methods: Total PA across different domains (recreation, occupation, transport, household) was reported for ages 14 and 30 years, and when responding to the questionnaire (31– 76 years) using a 10-point scale, validated to rank PA levels in Norwegian females. We estimated life-course PA trajectories using a latent class mixed model in 152,248 women divided into three subcohorts depending on age at questionnaire completion: 31– 39 (n = 27,098), 40– 49 (n = 52,515) and ≥ 50 years (n = 72,635). The unique 11-digit identity number of Norwegian citizens was used to link NOWAC to the Cancer Registry of Norway for information on cancer diagnoses, emigration and death. Associations between PA trajectories and melanoma risk were estimated in each subcohort using multivariable Cox regression.Results: Five classes of individual life-course PA trajectories were identified in subcohort 31– 39 years (low, moderate, high, decreasing, increasing PA) and four in subcohorts 40– 49 and ≥ 50 years (low, moderate, high, decreasing PA). No significant association was found between life-course PA trajectories and melanoma risk in any subcohort. Hazard ratios (95% confidence intervals) for the high versus moderate trajectory were 0.92 (0.66– 1.29), 1.15 (0.97– 1.37) and 0.90 (0.78– 1.05) for subcohorts 31– 39, 40– 49 and ≥ 50 years, respectively.Conclusion: Our results do not support a positive association between PA and melanoma risk found in previous studies, which is important for public health guidelines promoting regular PA.Keywords: physical activity, cutaneous melanoma, trajectory, cohort, women, Norway

Leon Alexander Mclaren Berge,1– 3 Bettina Kulle Andreassen,1 Jo Steinson Stenehjem,1,2,4 Trond Heir,5,6 Øystein Karlstad,7 Asta Juzeniene,8 Reza Ghiasvand,1,9 Inger Kristin Larsen,10 Adele C Green,11,12 Marit Bragelien Veierød,2 Trude Eid Robsahm1,3 1Department of Research, Cancer Registry of Norway, Oslo, Norway; 2Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; 3Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; 4Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway; 5Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; 6Oslo Ischemia Study, Oslo University Hospital, Oslo, Norway; 7Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway; 8Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; 9Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway; 10Department of Registration, Cancer Registry of Norway, Oslo, Norway; 11Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia; 12Molecular Oncology Unit, CRUK Manchester Institute, University of Manchester, Manchester, UKCorrespondence: Leon Alexander Mclaren BergeCancer Registry of Norway, Majorstuen, Oslo N-0304, NorwayTel +47 99605034Email Leon.Berge@kreftregisteret.noPurpose: Cutaneous melanoma is among the fastest growing malignancies in Norway and ultraviolet radiation (UVR) exposure is the primary environmental risk factor. Immunomodulating drugs can increase skin photosensitivity and suppress immune responses, and by such mechanisms influence melanoma risk. We, therefore, aimed to examine the associations between use of immunomodulating drugs and melanoma risk, at a nationwide population level.Patients and Methods: In the Cancer Registry of Norway, we identified all cases aged 18– 85 with a first primary cutaneous melanoma diagnosed in 2007– 2015 (n=12,106). These were matched to population controls from the Norwegian National Registry 1:10 (n=118,564), on sex and year of birth using risk set sampling. Information on prescribed drugs (2004– 2015) was obtained by linkage to the Norwegian Prescription Database (NorPD). Conditional logistic regression was used to estimate rate ratios (RRs) and 95% confidence intervals (CIs) for associations between use of immunomodulating drugs (immunosuppressants and corticosteroids) and melanoma risk, adjusted for ambient UVR and other drug use.Results: Compared with ≤ 1 prescription, use of ≥ 8 prescriptions of immunosuppressants was associated with increased risk of melanoma (RR 1.50, 95% CI 1.27, 1.77). Similar associations were found for subgroups of immunosuppressants: drugs typically prescribed to organ transplant recipients (OTRs) (RR 2.02, 95% CI 1.35, 3.03) and methotrexate (RR 1.27, 95% CI 1.04, 1.55). Similar results were found for high levels of cumulative doses and across all histological subtypes. Use of corticosteroids was not associated with melanoma risk.Conclusion: We found a positive association between use of immunosuppressants and melanoma risk, with the highest risk seen for drugs prescribed to OTRs. Knowledge about this risk increase is important for physicians and users of these drugs, for intensified surveillance, awareness and cautious sun exposure.Keywords: immunosuppressants, corticosteroids, melanoma, prescription drugs, pharmacoepidemiology, registry-based